A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy. The researchers evaluated 45 men who had initially responded [...]
Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]
I know, we all have our prostate cancer story where we are told how lucky we are that we have prostate cancer. The conversation goes on something like, “Oh you are so lucky, you have the GOOD cancer, you should be so thankful.” Then it is often followed up by something like, “My (father) (brother) [...]
The common question when we are diagnosed with prostate cancer is how long do I have to live? The exact same question is asked again when we discover that we have had a prostate cancer recurrence. Times have changed and so has our potential life span. In the late 1980s and early 1990s men diagnosed [...]
Findings from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial indicate that the strongest predictors of prostate cancer-specific mortality include Gleason 7, body mass index >30, African-American race, PSA level, stage, and high co-morbidity score. Understanding how non-tumor factors affect prostate cancer-specific mortality will help identify those men who may benefit from screening and [...]